Biotechnology Sector

An Expert's View about Biotechnology in Switzerland

Posted on: 29 Aug 2012

With 174 biotech companies and 63 biotech suppliers, Switzerland has the world’s highest per capita biotech density.

Biotechnology Sector in Switzerland With 174 biotech companies and 63 biotech suppliers, Switzerland has the world’s highest per capita biotech density. In 2010, the Swiss biotech industry generated a turnover of CHF 9.2 billion and had a workforce of over 19,000. Market overview Switzerland maintains a leading position in the global pharmaceutical and biotech industries. The city of Basle is a European centre of “big pharma”, and the country’s strong biotech industry is nearing maturity. Switzerland is an advanced pharmaceutical market. Per-capita expenditure on drugs is among the highest in the world. Consumption centres around patented pharmaceuticals, with Switzerland providing a ready market for cutting-edge therapies. Meanwhile, high levels of out of-pocket expenditure have resulted in the development of a mature and competitive consumer health sector. Key opportunities The Swiss market comprises a spread of company types, ranging from “big pharma” and other larger-sized biopharma companies to small-to-medium sized companies and start-ups. In general, Swiss companies are open to international partnerships and cooperation. Because of the strengths of indigenous industry, opportunities for British companies are mainly in areas of scientific/technological collaboration, and supply of services: ξ Human Life Sciences (new compounds and molecules, drug delivery technology) ξ Rising interest in nutraceuticals ξ Contract Research Organisations ξ Instrumentation, systems and equipment Latest export opportunities – Biotech Latest export opportunities – Switzerland Getting into the market Biotech and pharma companies enjoy a favourable regulatory and administrative environment in Switzerland. Product registration cycles are short and innovative drugs, biotech products and services enjoy easy access to the markets. Switzerland has good contractual relations with the European Union and in many cases legislation is harmonised. Swiss companies typically have considerable financial strength and invest significantly in R&D. They are global in their outlook and favourable to international business relationships. More about doing business in Switzerland Contacts Market intelligence is critical when doing business overseas, and UKTI can provide bespoke market research and support during overseas visits though our chargeable Overseas Market Introduction Service (OMIS). To commission research or for general advice about the market, get in touch with our specialists in country - or contact your local international trade team. ξ Eleanor Baha, British Embassy – UKTI Geneva. Tel: +41 (0)22 918 24 21 or email: ξ Marie Gow, British Embassy – UKTI Geneva. Tel: +41 (0)22 918 24 78 or email: Contact your local international trade team Events UKTI runs a range of events for exporters, including seminars in the UK, trade missions to overseas markets and support for attendance at overseas trade shows. For a detailed listing of events in Switzerland please consult Latest events – Biotech Useful links More about OMIS and other UKTI services for exporters
Posted: 29 August 2012

See more from Biotechnology in Switzerland

Expert Views    
Biotechnology Switzerland   By UK Trade & Investment
Micro- and Nanotechnology Switzerland   By UK Trade & Investment
Biotechnology Sector   By UK Trade & Investment